Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29994784 | 0.77 | GPR35 (0.36) | GPR35 | |
| SCHEMBL441091 | 0.77 | GPR35 (0.41) | GPR35PIP4K2CGPR119MAPTNPC1 | |
| SCHEMBL441195 | 0.76 | AXL (0.37) | GPR35PIP4K2CALDH1A1GPR119MAPT | |
| SCHEMBL30808244 | 0.76 | AXL (0.37) | GPR35PIP4K2CALDH1A1GPR119MAPT | |
| SCHEMBL21822980 | 0.75 | GPR35 (0.37) | GPR35PIP4K2CALDH1A1GPR119MAPT | |
| SCHEMBL439290 | 0.75 | MAPT (0.35) | ALDH1A1MAPTNPC1PKMMEN1 | |
| SCHEMBL13920413 | 0.75 | NPC1 (0.47) | ALDH1A1MAPTNPC1PKMMEN1 | |
| SCHEMBL13920414 | 0.73 | MAPT (0.32) | ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL21823085 | 0.73 | MAPK1 (0.42) | GPR35PIP4K2CGPR119NPC1PKM | |
| SCHEMBL28606328 | 0.73 | PIP4K2C (0.42) | GPR35PIP4K2CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616471-B1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2616471-B1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2014-12-31 | — | — | EP | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | BARBOSA JOSEPH (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2616471-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | Lexicon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037141-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065200-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | GPR35 3233/4885PIP4K2C 3244/4885ALDH1A1 1305/4885 |
| US-20140288071-A1 | INHIBITORS OF NOTUM PECTINACETYLESTERASE AND METHODS OF THEIR USE | NOTUM, GLA, CES1 | GPR35 3233/4885PIP4K2C 3244/4885ALDH1A1 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.